Our combined data indicate a novel aspect of ibrutinib efficacy, specifically its potential capacity to interrupt TLR9-induced CD40 upregulation and protein translation, which normally primes CLL cells in the LN environment for venetoclax resistance. Here, TLR9 is linked to B-cell chronic lymphocytic leukemia.